Sample/JJ
Size/NN
and/CC
Statistical/JJ
Power/NN
Calculation/NN
in/IN
Genetic/JJ
Association/NN
Studies/NNS
./.
====================
A/DT
sample/JJ
size/NN
with/IN
sufficient/JJ
statistical/JJ
power/JJR
is/VBZ
critical/JJ
to/TO
the/DT
success/NN
of/IN
genetic/JJ
association/NN
studies/NNS
to/TO
detect/VB
causal/JJ
genes/NNS
of/IN
human/JJ
complex/NN
diseases/NNS
./.
====================
Genome-wide/NN
association/NN
studies/NNS
require/VBP
much/RB
larger/JJR
sample/NN
sizes/NNS
to/TO
achieve/VB
an/DT
adequate/NN
statistical/JJ
power/NN
./.
====================
We/PRP
estimated/VBD
the/DT
statistical/JJ
power/JJR
with/IN
increasing/VBG
numbers/NNS
of/IN
markers/NNS
analyzed/VBD
and/CC
compared/VBD
the/DT
sample/NN
sizes/NNS
that/DT
were/VBD
required/VBN
in/IN
case-control/JJ
studies/NNS
and/CC
case-parent/JJ
studies/NNS
./.
====================
We/PRP
computed/VBD
the/DT
effective/JJ
sample/NN
size/NN
and/CC
statistical/JJ
power/NN
using/VBG
Genetic/JJ
Power/NN
Calculator/NN
./.
====================
An/DT
analysis/NN
using/VBG
a/DT
larger/JJR
number/NN
of/IN
markers/NNS
requires/VBZ
a/DT
larger/JJR
sample/NN
size/NN
./.
====================
Testing/VBG
a/DT
single-nucleotide/JJ
polymorphism/NN
(/(
SNP/NN
)/)
marker/NN
requires/VBZ
248/CD
cases/NNS
,/,
while/IN
testing/VBG
500,000/CD
SNPs/NNS
and/CC
1/CD
million/NN
markers/NNS
requires/VBZ
1,206/CD
cases/NNS
and/CC
1,255/CD
cases/NNS
,/,
respectively/RB
,/,
under/IN
the/DT
assumption/NN
of/IN
an/DT
odds/NNS
ratio/NN
of/IN
2/CD
,/,
5/CD
%/NN
disease/NN
prevalence/NN
,/,
5/CD
%/NN
minor/JJ
allele/NN
frequency/NN
,/,
complete/JJ
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
,/,
1:1/CD
case/control/JJ
ratio/NN
,/,
and/CC
a/DT
5/CD
%/NN
error/JJ
rate/NN
in/IN
an/DT
allelic/JJ
test/NN
./.
====================
Under/IN
a/DT
dominant/JJ
model/NN
,/,
a/DT
smaller/JJR
sample/NN
size/NN
is/VBZ
required/VBN
to/TO
achieve/VB
80/CD
%/NN
power/JJR
than/IN
other/JJ
genetic/JJ
models/NNS
./.
====================
We/PRP
found/VBD
that/IN
a/DT
much/RB
lower/JJR
sample/NN
size/NN
was/VBD
required/VBN
with/IN
a/DT
strong/JJ
effect/NN
size/NN
,/,
common/JJ
SNP/NN
,/,
and/CC
increased/VBD
LD/NN
./.
====================
In/IN
addition/NN
,/,
studying/VBG
a/DT
common/JJ
disease/NN
in/IN
a/DT
case-control/JJ
study/NN
of/IN
a/DT
1:4/CD
case-control/JJ
ratio/NN
is/VBZ
one/CD
way/NN
to/TO
achieve/VB
higher/JJR
statistical/JJ
power/JJR
./.
====================
We/PRP
also/RB
found/VBD
that/IN
case-parent/JJ
studies/NNS
require/VBP
more/RBR
samples/NNS
than/IN
case-control/JJ
studies/NNS
./.
====================
Although/IN
we/PRP
have/VBP
not/RB
covered/VBN
all/DT
plausible/JJ
cases/NNS
in/IN
study/NN
design/NN
,/,
the/DT
estimates/NNS
of/IN
sample/JJ
size/NN
and/CC
statistical/JJ
power/JJR
computed/VBN
under/IN
various/JJ
assumptions/NNS
in/IN
this/DT
study/NN
may/MD
be/VB
useful/JJ
to/TO
determine/VB
the/DT
sample/JJ
size/NN
in/IN
designing/VBG
a/DT
population-based/JJ
genetic/JJ
association/NN
study/NN
./.
====================
In/IN
genetic/JJ
epidemiological/JJ
research/NN
,/,
both/CC
case-control/JJ
and/CC
case-parent/JJ
trio/NN
designs/VBZ
have/VBP
been/VBN
used/VBN
widely/RB
to/TO
evaluate/VB
genetic/JJ
susceptibilities/NNS
to/TO
human/JJ
complex/NN
diseases/NNS
and/CC
markers/NNS
,/,
such/JJ
as/IN
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
,/,
to/TO
localize/VB
disease/NN
gene/NN
variants/NNS
[/(
1-5/CD
]/)
./.
====================
The/DT
sample/JJ
size/NN
for/IN
detecting/VBG
associations/NNS
between/IN
disease/NN
and/CC
SNP/NN
markers/NNS
is/VBZ
known/VBN
to/TO
be/VB
highly/RB
affected/VBN
by/IN
disease/NN
prevalence/NN
,/,
disease/NN
allele/NN
frequency/NN
,/,
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
,/,
inheritance/RB
models/NNS
(/(
e.g./FW
,/,
additive/JJ
,/,
dominant/JJ
,/,
and/CC
multiplicative/JJ
models/NNS
)/)
,/,
and/CC
effect/NN
size/NN
of/IN
the/DT
genetic/JJ
variants/NNS
(/(
e.g./FW
,/,
odds/NNS
ratio/NN
,/,
relative/JJ
risk/NN
,/,
etc/JJ
./.
)/)
====================
[/(
4/CD
,/,
6/CD
,/,
7/CD
]/)
./.
====================
Previous/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
a/DT
population/NN
based/VBN
case-control/JJ
design/NN
can/MD
be/VB
more/RBR
powerful/JJ
than/IN
a/DT
family-based/JJ
study/NN
design/NN
in/IN
identifying/VBG
genes/NNS
predisposing/VBG
human/JJ
complex/NN
traits/VBZ
,/,
both/CC
for/IN
qualitative/JJ
traits/VBZ
and/CC
for/IN
quantitative/JJ
traits/VBZ
[/(
8-11/CD
]/)
./.
====================
However/RB
,/,
some/DT
studies/NNS
reported/VBD
that/IN
the/DT
case-parent/JJ
design/NN
is/VBZ
much/RB
more/RBR
powerful/JJ
than/IN
the/DT
case-control/JJ
design/NN
in/IN
evaluating/VBG
genetic/JJ
risk/NN
for/IN
common/JJ
complex/NN
diseases/NNS
,/,
because/IN
case-control/JJ
studies/NNS
are/VBP
susceptible/JJ
to/TO
bias/NNS
due/JJ
to/TO
phenotype/NN
misclassification/NN
or/CC
population/NN
stratification/NN
[/(
12/CD
,/,
13/CD
]/)
./.
====================
Recently/RB
,/,
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
using/VBG
thousands/NNS
of/IN
cases/NNS
and/CC
controls/VBZ
reported/VBD
many/JJ
susceptibility/NN
SNPs/NNS
for/IN
237/CD
human/JJ
traits/VBZ
by/IN
the/DT
end/NN
of/IN
June/JJ
,/,
2011/CD
(/(
www.genome.gov/GWAStudies/NNS
)/)
./.
====================
Since/IN
a/DT
GWAS/JJ
evaluates/VBZ
hundreds/VBZ
of/IN
thousands/NNS
of/IN
SNP/NN
markers/NNS
,/,
it/PRP
requires/VBZ
a/DT
much/RB
larger/JJR
sample/JJ
size/NN
to/TO
achieve/VB
an/DT
adequate/NN
statistical/JJ
power/JJR
[/(
14-18/CD
]/)
./.
====================
In/IN
genetic/JJ
association/NN
studies/NNS
,/,
the/DT
observed/VBN
signal/NN
for/IN
association/NN
is/VBZ
referred/VBN
to/TO
be/VB
statistically/RB
significant/JJ
if/IN
the/DT
p-value/JJ
is/VBZ
less/RBR
than/IN
a/DT
preset/NN
threshold/JJ
value/NN
(/(
α/LS
)/)
of/IN
0.05/CD
to/TO
reject/VB
a/DT
null/JJ
hypothesis/NN
of/IN
genetic/JJ
association/NN
./.
====================
Testing/VBG
a/DT
large/JJ
number/NN
of/IN
SNP/NN
markers/NNS
leads/VBZ
to/TO
a/DT
large/JJ
number/NN
of/IN
multiple/JJ
comparisons/NNS
and/CC
thus/RB
increases/VBZ
false/VBP
positive/JJ
rates/NNS
./.
====================
Either/DT
the/DT
Bonferroni/NN
correction/NN
or/CC
the/DT
false/NN
discovery/NN
rate/NN
is/VBZ
generally/RB
applied/VBN
to/TO
avoid/VB
false/VBP
positive/JJ
(/(
type/NN
I/CD
error/NN
)/)
rates/NNS
./.
====================
However/RB
,/,
the/DT
Bonferroni-corrected/JJ
p-value/JJ
,/,
the/DT
significance/NN
threshold/RB
set/NN
to/TO
0.05/CD
divided/VBN
by/IN
the/DT
total/JJ
number/NN
of/IN
SNPs/NNS
analyzed/VBD
in/IN
a/DT
GWAS/JJ
,/,
is/VBZ
too/RB
strict/JJ
to/TO
consider/VB
the/DT
correlations/NNS
among/IN
SNP/NN
markers/NNS
(/(
e.g./FW
,/,
p/NN
=/JJ
1/CD
×/NN
10-7/CD
for/IN
500,000/CD
(/(
500/CD
K/NN
)/)
SNPs/NNS
,/,
p/NN
=/JJ
5/CD
×/NN
10-8/CD
for/IN
1/CD
million/NN
(/(
M/NN
)/)
SNPs/NNS
)/)
[/(
16/CD
,/,
19/CD
]/)
./.
====================
Therefore/RB
,/,
estimating/VBG
a/DT
sufficient/JJ
sample/NN
size/NN
to/TO
achieve/VB
adequate/NN
statistical/JJ
power/JJR
is/VBZ
critical/JJ
in/IN
the/DT
design/NN
stage/NN
of/IN
genetic/JJ
association/NN
[/(
20-24/CD
]/)
./.
====================
Statistical/JJ
power/JJR
is/VBZ
the/DT
probability/NN
to/TO
reject/VB
a/DT
null/JJ
hypothesis/NN
(/(
H0/NN
)/)
while/IN
the/DT
alternative/JJ
hypothesis/NN
(/(
HA/NN
)/)
is/VBZ
true/JJ
./.
====================
It/PRP
is/VBZ
affected/VBN
by/IN
many/JJ
factors/NNS
./.
====================
For/IN
instance/NN
,/,
a/DT
larger/JJR
sample/NN
size/NN
is/VBZ
required/VBN
to/TO
achieve/VB
sufficient/JJ
statistical/JJ
power/NN
./.
====================
Although/IN
a/DT
researcher/JJ
collects/NNS
a/DT
large/JJ
number/NN
of/IN
samples/NNS
,/,
all/DT
samples/NNS
may/MD
not/RB
be/VB
necessary/JJ
to/TO
be/VB
analyzed/VBN
to/TO
detect/VB
evidence/NN
for/IN
association/NN
./.
====================
A/DT
large/JJ
sample/JJ
size/NN
improves/VBZ
the/DT
ability/NN
of/IN
disease/NN
prediction/NN
;/:
however/RB
,/,
it/PRP
is/VBZ
not/RB
cost-effective/JJ
that/DT
a/DT
researcher/JJ
genotypes/NNS
more/RBR
than/IN
the/DT
effective/JJ
sample/NN
size/NN
[/(
25/CD
]/)
./.
====================
Unless/IN
researchers/NNS
estimate/NN
sample/NN
size/NN
and/CC
statistical/JJ
power/JJR
at/IN
the/DT
research/NN
design/NN
stage/NN
,/,
it/PRP
leads/VBZ
to/TO
wasted/VBN
time/NN
and/CC
resources/VBZ
to/TO
collect/VB
samples/NNS
./.
====================
An/DT
effective/JJ
sample/NN
size/NN
can/MD
be/VB
defined/VBN
as/IN
the/DT
minimum/JJ
number/NN
of/IN
samples/NNS
that/DT
achieves/VBZ
adequate/NN
statistical/JJ
power/JJR
(/(
e.g./FW
,/,
80/CD
%/NN
power/JJR
)/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
too/RB
small/JJ
a/DT
sample/JJ
size/NN
to/TO
detect/VB
true/JJ
evidence/NN
for/IN
an/DT
association/NN
increases/VBZ
false/VBP
negative/JJ
rates/NNS
and/CC
reduces/VBZ
the/DT
reliability/NN
of/IN
a/DT
study/NN
./.
====================
False/NN
negative/JJ
rates/NNS
are/VBP
increased/VBN
by/IN
multiple/JJ
factors/NNS
that/WDT
cause/VBP
systematic/JJ
biases/NNS
,/,
and/CC
such/JJ
biases/NNS
reduce/VBP
statistical/JJ
power/JJR
[/(
26/CD
]/)
./.
====================
The/DT
statistical/JJ
power/JJR
of/IN
80/CD
%/NN
is/VBZ
used/VBN
widely/RB
to/TO
avoid/VB
false/VBP
negative/JJ
associations/NNS
and/CC
to/TO
determine/VB
a/DT
cost-effective/JJ
sample/NN
size/NN
in/IN
large-scale/JJ
association/NN
studies/NNS
[/(
7/CD
,/,
22/CD
,/,
23/CD
]/)
./.
====================
However/RB
,/,
many/JJ
researchers/NNS
tend/VBP
to/TO
overlook/VB
the/DT
importance/NN
of/IN
statistical/JJ
power/JJR
and/CC
sample/NN
size/NN
calculations/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
evaluated/VBD
statistical/JJ
power/JJR
with/IN
increasing/VBG
numbers/NNS
of/IN
markers/NNS
analyzed/VBD
under/IN
various/JJ
assumptions/NNS
and/CC
compared/VBD
the/DT
sample/NN
sizes/NNS
required/VBN
in/IN
case-control/JJ
studies/NNS
and/CC
case-parent/JJ
studies/NNS
./.
====================
We/PRP
computed/VBD
the/DT
effective/JJ
sample/NN
size/NN
and/CC
statistical/JJ
power/JJR
using/VBG
a/DT
web/JJ
browser/JJR
program/NN
,/,
Genetic/JJ
Power/NN
Calculator/NN
developed/VBD
by/IN
Purcell/NN
et/FW
al/JJ
./.
====================
[/(
27/CD
]/)
(/(
http/NN
:/:
//pngu.mgh.harvard.edu/~purcell/gpc//JJ
)/)
,/,
for/IN
both/DT
case-control/JJ
and/CC
case-parent/JJ
studies/NNS
./.
====================
We/PRP
conducted/VBD
power/JJR
and/CC
sample/JJ
size/NN
calculations/NNS
under/IN
various/JJ
assumptions/NNS
about/RB
genetic/JJ
models/NNS
(/(
i.e./FW
,/,
allelic/JJ
,/,
additive/JJ
,/,
dominant/JJ
,/,
recessive/JJ
,/,
and/CC
co-dominant/JJ
models/NNS
)/)
,/,
minor/JJ
allele/NN
frequencies/NNS
(/(
MAFs/NNS
)/)
,/,
pair-wise/JJ
LD/NN
,/,
disease/NN
prevalence/NN
,/,
case-to-control/JJ
ratio/NN
,/,
and/CC
number/NN
of/IN
SNP/NN
markers/NNS
(/(
i.e./FW
,/,
single/JJ
SNP/NN
,/,
500/CD
K/NN
SNPs/NNS
,/,
and/CC
1/CD
M/NN
SNPs/NNS
)/)
./.
====================
The/DT
values/NNS
tested/VBN
for/IN
heterozygous/JJ
odds/NNS
ratio/NN
(/(
ORhet/NN
)/)
were/VBD
1.3/CD
,/,
1.5/CD
,/,
2/CD
,/,
and/CC
2.5/CD
./.
====================
The/DT
power/RBR
and/CC
sample/JJ
sizes/NNS
were/VBD
calculated/VBN
under/IN
different/JJ
ranges/NNS
of/IN
factors/NNS
,/,
such/JJ
as/IN
MAF/NN
of/IN
5/CD
%/NN
,/,
10/CD
%/NN
,/,
20/CD
%/NN
,/,
and/CC
30/CD
%/NN
;/:
LD/NN
of/IN
0.4/CD
,/,
0.6/CD
,/,
0.8/CD
,/,
and/CC
1/CD
;/:
disease/NN
prevalence/NN
of/IN
0.01/CD
%/NN
,/,
0.1/CD
%/NN
,/,
5/CD
%/NN
,/,
and/CC
10/CD
%/NN
;/:
and/CC
case-to-control/JJ
ratio/NN
of/IN
1:1/CD
,/,
1:2/CD
,/,
1:3/CD
,/,
and/CC
1:4/CD
./.
====================
We/PRP
assumed/VBD
Hardy-Weinberg/JJ
equilibrium/NN
at/IN
the/DT
disease-susceptible/JJ
allele/NN
./.
====================
The/DT
Bonferroni/NNP
p-value/JJ
that/IN
was/VBD
specific/JJ
to/TO
the/DT
number/NN
of/IN
SNP/NN
makers/VBZ
tested/VBN
was/VBD
applied/VBN
to/TO
cover/RB
3/CD
billion/NN
base/NN
pairs/NNS
of/IN
the/DT
human/JJ
genome/NN
(/(
i.e./FW
,/,
p/NN
=/JJ
0.05/CD
for/IN
a/DT
single/JJ
SNP/NN
marker/NN
,/,
p/NN
=/JJ
1/CD
×/NN
10-7/CD
for/IN
500/CD
K/NN
SNP/NN
markers/NNS
,/,
and/CC
p/NN
=/JJ
5/CD
×/NN
10-8/CD
for/IN
1/CD
M/NN
SNP/NN
markers/NNS
)/)
./.
====================
We/PRP
fixed/VBD
the/DT
proper/JJ
range/NN
of/IN
sample/JJ
sizes/NNS
from/IN
100/CD
to/TO
2,000/CD
cases/NNS
,/,
because/IN
the/DT
power/JJ
is/VBZ
too/RB
low/JJ
when/WRB
the/DT
sample/JJ
size/NN
is/VBZ
below/IN
100/CD
cases/NNS
(/(
or/CC
trios/NNS
)/)
,/,
and/CC
the/DT
cost/JJ
is/VBZ
too/RB
high/JJ
to/TO
realistically/RB
collect/JJ
samples/NNS
when/WRB
the/DT
sample/JJ
size/NN
is/VBZ
above/JJ
2,000/CD
[/(
7/CD
,/,
22/CD
]/)
./.
====================
We/PRP
calculated/VBD
the/DT
sample/JJ
size/NN
to/TO
achieve/VB
80/CD
%/NN
statistical/JJ
power/JJR
according/VBG
to/TO
the/DT
genetic/JJ
models/NNS
and/CC
the/DT
heterozygous/JJ
ORs/NNS
using/VBG
a/DT
single/JJ
SNP/NN
marker/NN
in/IN
a/DT
case-control/JJ
study/NN
under/IN
the/DT
assumptions/NNS
of/IN
5/CD
%/NN
disease/NN
prevalence/NN
,/,
5/CD
%/NN
MAF/NN
,/,
complete/JJ
LD/NN
,/,
1:1/CD
case-to-control/JJ
ratio/NN
,/,
and/CC
5/CD
%/NN
type/NN
I/CD
error/NN
rate/NN
(/(
α/RB
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
The/DT
dominant/JJ
model/NN
required/VBN
the/DT
smallest/JJS
sample/NN
size/NN
to/TO
achieve/VB
80/CD
%/NN
power/JJR
compared/VBN
to/TO
other/JJ
genetic/JJ
models/NNS
(/(
e.g./FW
,/,
90/CD
cases/NNS
)/)
./.
====================
In/IN
contrast/NN
,/,
the/DT
effective/JJ
sample/NN
size/NN
to/TO
test/VB
a/DT
single/JJ
SNP/NN
under/IN
the/DT
recessive/JJ
model/NN
was/VBD
too/RB
large/JJ
to/TO
collect/VB
with/IN
a/DT
limited/JJ
budget/NN
,/,
even/RB
if/IN
the/DT
homozygous/JJ
OR/NN
is/VBZ
greater/JJR
than/IN
4/CD
(/(
e.g./FW
,/,
1,536/CD
cases/NNS
)/)
./.
====================
It/PRP
reveals/VBZ
difficulty/NN
in/IN
detecting/VBG
a/DT
disease/NN
allele/NN
that/DT
follows/VBZ
a/DT
recessive/JJ
mode/NN
of/IN
inheritance/NN
with/IN
a/DT
moderate/JJ
sample/NN
size/NN
./.
====================
The/DT
sample/JJ
size/NN
and/CC
statistical/JJ
power/JJR
for/IN
the/DT
allelic/JJ
test/NN
in/IN
a/DT
case-control/JJ
study/NN
under/IN
the/DT
different/JJ
assumptions/NNS
of/IN
ORhet/JJ
,/,
MAF/NN
,/,
disease/NN
prevalence/NN
,/,
LD/NN
,/,
and/CC
case-to-control/JJ
ratio/NN
by/IN
allowing/VBG
a/DT
5/CD
%/NN
type/NN
I/CD
error/NN
rate/NN
are/VBP
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
As/IN
shown/VBN
in/IN
Fig/NN
./.
====================
1A/NN
,/,
a/DT
lower/JJR
sample/JJ
size/NN
was/VBD
required/VBN
to/TO
test/VB
allelic/JJ
association/NN
for/IN
a/DT
single/JJ
SNP/NN
with/IN
a/DT
larger/RBR
MAF/NN
at/IN
the/DT
same/JJ
risk/NN
of/IN
disease/NN
(/(
OR/NN
)/)
under/IN
the/DT
assumptions/NNS
of/IN
5/CD
%/NN
disease/NN
prevalence/NN
,/,
5/CD
%/NN
α/IN
,/,
complete/JJ
LD/NN
,/,
and/CC
1:1/CD
case-to-control/JJ
ratio/NN
./.
====================
The/DT
minimum/JJ
number/NN
of/IN
cases/NNS
decreased/VBD
from/IN
1,974/CD
cases/NNS
for/IN
a/DT
SNP/NN
with/IN
a/DT
MAF/NN
of/IN
5/CD
%/NN
to/TO
545/CD
cases/NNS
for/IN
a/DT
SNP/NN
with/IN
a/DT
MAF/NN
of/IN
30/CD
%/NN
under/IN
the/DT
same/JJ
assumption/NN
./.
====================
A/DT
high-risk/JJ
allele/NN
showing/VBG
a/DT
high/JJ
OR/NN
requires/VBZ
a/DT
smaller/JJR
sample/NN
size/NN
to/TO
be/VB
detected/VBN
under/IN
the/DT
same/JJ
assumption/NN
./.
====================
While/IN
an/DT
allele/NN
with/IN
an/DT
OR/NN
of/IN
1.3/CD
requires/VBZ
1,974/CD
cases/NNS
and/CC
1,974/NN
controls/VBZ
to/TO
be/VB
significantly/RB
detected/VBN
in/IN
a/DT
case-control/JJ
study/NN
,/,
a/DT
SNP/NN
with/IN
an/DT
OR/NN
of/IN
2.5/CD
can/MD
be/VB
detected/VBN
in/IN
a/DT
study/NN
of/IN
134/CD
cases/NNS
and/CC
134/CD
controls/VBZ
under/IN
the/DT
assumption/NN
of/IN
a/DT
MAF/NN
of/IN
5/CD
%/NN
,/,
disease/NN
prevalence/NN
of/IN
5/CD
%/NN
,/,
type/NN
I/CD
error/CC
rate/NN
of/IN
5/CD
%/NN
,/,
and/CC
D/NN
'/``
of/IN
1/CD
(/(
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
The/DT
higher/JJR
prevalence/RB
and/CC
the/DT
higher/JJR
LD/NN
were/VBD
associated/VBN
with/IN
increased/VBN
statistical/JJ
power/RB
:/:
for/IN
instance/RB
,/,
as/IN
the/DT
LD/NN
increased/VBD
from/IN
0.4/CD
to/TO
0.6/CD
,/,
0.8/CD
,/,
and/CC
1/CD
,/,
the/DT
statistical/JJ
power/RB
obtained/VBN
from/IN
a/DT
study/NN
of/IN
1,000/CD
cases/NNS
and/CC
1,000/CD
controls/VBZ
was/VBD
obviously/RB
increased/VBD
from/IN
26.5/CD
%/NN
to/TO
49.2/CD
%/NN
,/,
72.8/CD
%/NN
,/,
and/CC
88.4/CD
%/NN
,/,
respectively/RB
,/,
under/IN
the/DT
assumption/NN
of/IN
OR/NN
1.3/CD
,/,
5/CD
%/NN
MAF/NN
,/,
5/CD
%/NN
prevalence/NN
,/,
and/CC
5/CD
%/NN
α/IN
level/NN
(/(
Fig/NN
./.
====================
1B/NN
and/CC
1C/NN
)/)
./.
====================
In/IN
addition/NN
,/,
a/DT
1:4/CD
case-to-control/JJ
ratio/NN
,/,
which/WDT
is/VBZ
the/DT
golden/NN
standard/JJ
ratio/NN
for/IN
the/DT
numbers/NNS
of/IN
cases/NNS
and/CC
controls/VBZ
to/TO
be/VB
collected/VBN
in/IN
a/DT
case-control/JJ
study/NN
,/,
showed/VBD
the/DT
most/JJS
effective/JJ
sample/NN
size/NN
to/TO
achieve/VB
80/CD
%/NN
statistical/JJ
power/JJR
./.
====================
In/IN
many/JJ
clinical/JJ
settings/NNS
,/,
researchers/NNS
are/VBP
able/JJ
to/TO
obtain/VB
more/RBR
data/NNS
from/IN
affected/VBN
individuals/NNS
than/IN
healthy/JJ
individuals/NNS
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
there/EX
are/VBP
more/RBR
healthy/JJ
participants/NNS
than/IN
participants/NNS
with/IN
a/DT
disease/NN
in/IN
a/DT
population-based/JJ
study/NN
./.
====================
Therefore/RB
,/,
the/DT
minimum/JJ
numbers/NNS
of/IN
cases/NNS
and/CC
controls/VBZ
required/VBD
to/TO
achieve/VB
80/CD
%/NN
statistical/JJ
power/JJR
depend/VBP
on/IN
the/DT
study/NN
design/NN
./.
====================
For/IN
a/DT
SNP/NN
with/IN
an/DT
allelic/JJ
OR/NN
of/IN
2/CD
and/CC
5/CD
%/NN
MAF/NN
,/,
127/CD
cases/NNS
and/CC
508/CD
controls/VBZ
are/VBP
required/VBN
in/IN
the/DT
case/NN
of/IN
a/DT
1:4/CD
case-control/JJ
ratio/NN
,/,
whereas/IN
248/CD
cases/NNS
and/CC
248/CD
controls/VBZ
are/VBP
required/VBN
in/IN
the/DT
case/NN
of/IN
a/DT
1:1/CD
ratio/NN
to/TO
achieve/VB
80/CD
%/NN
statistical/JJ
power/JJR
under/IN
the/DT
assumption/NN
of/IN
5/CD
%/NN
prevalence/NN
,/,
complete/JJ
LD/NN
,/,
and/CC
5/CD
%/NN
α/IN
level/NN
./.
====================
In/IN
Table/JJ
2/CD
,/,
we/PRP
compared/VBD
the/DT
number/NN
of/IN
cases/NNS
to/TO
the/DT
number/NN
of/IN
case-parent/JJ
trios/NNS
to/TO
perform/VB
a/DT
case-control/JJ
study/NN
and/CC
a/DT
study/NN
using/VBG
case-parent/JJ
trios/NNS
by/IN
increasing/VBG
the/DT
number/NN
of/IN
SNPs/NNS
being/VBG
analyzed/VBN
./.
====================
Genetic/JJ
association/NN
studies/NNS
with/IN
larger/JJR
numbers/NNS
of/IN
SNP/NN
markers/NNS
require/VBP
a/DT
larger/JJR
sample/NN
size/NN
to/TO
reduce/VB
false/VBP
positive/JJ
association/NN
due/JJ
to/TO
testing/VBG
multiple/JJ
hypotheses/NNS
./.
====================
The/DT
sample/JJ
size/NN
required/VBN
in/IN
a/DT
case-parent/JJ
study/NN
is/VBZ
generally/RB
larger/RBR
than/IN
that/DT
of/IN
a/DT
case-control/JJ
study/NN
design/NN
./.
====================
For/IN
instance/NN
,/,
248/CD
cases/NNS
and/CC
248/CD
controls/VBZ
(/(
496/CD
individuals/NNS
)/)
were/VBD
required/VBN
to/TO
detect/VB
a/DT
SNP/NN
with/IN
an/DT
ORhet/NN
of/IN
2/CD
and/CC
5/CD
%/NN
MAF/NN
in/IN
a/DT
case-control/JJ
study/NN
,/,
whereas/IN
282/CD
case-parent/JJ
trios/NNS
(/(
846/CD
individuals/NNS
)/)
were/VBD
required/VBN
under/IN
the/DT
assumption/NN
of/IN
5/CD
%/NN
disease/NN
prevalence/NN
and/CC
complete/JJ
LD/NN
by/IN
allowing/VBG
a/DT
5/CD
%/NN
α/IN
level/NN
./.
====================
However/RB
,/,
the/DT
sample/NN
sizes/NNS
required/VBN
in/IN
both/CC
study/NN
designs/VBZ
increase/VBP
tremendously/RB
in/IN
a/DT
GWAS/JJ
./.
====================
Under/IN
the/DT
same/JJ
assumptions/NNS
as/IN
shown/VBN
above/IN
,/,
the/DT
number/NN
of/IN
samples/NNS
increased/VBD
from/IN
248/CD
cases/NNS
for/IN
a/DT
single/JJ
SNP/NN
analysis/NN
to/TO
1,206/CD
cases/NNS
and/CC
1,255/CD
cases/NNS
for/IN
analyses/NNS
of/IN
500/CD
K/NN
SNPs/NNS
and/CC
1/CD
M/NN
SNPs/NNS
,/,
respectively/RB
,/,
based/VBN
on/IN
the/DT
threshold/JJ
of/IN
p-value/JJ
,/,
calculated/VBN
using/VBG
a/DT
strict/JJ
Bonferroni/NNP
correction/NN
for/IN
multiple/JJ
hypotheses/NNS
comparisons/NNS
./.
====================
The/DT
statistical/JJ
power/JJR
to/TO
test/VB
the/DT
same/JJ
number/NN
of/IN
subjects/NNS
was/VBD
higher/JJR
for/IN
the/DT
case-control/JJ
design/NN
than/IN
for/IN
the/DT
case-parent/JJ
trio/NN
design/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Both/DT
designs/NNS
of/IN
the/DT
case-control/JJ
study/NN
and/CC
case-parent/JJ
study/NN
are/VBP
used/VBN
widely/RB
in/IN
the/DT
field/NN
of/IN
genetic/JJ
epidemiology/NN
for/IN
studying/VBG
associations/NNS
between/IN
genetic/JJ
factors/NNS
and/CC
the/DT
risk/NN
of/IN
disease/NN
./.
====================
Over/RB
the/DT
past/NN
2/CD
decades/NNS
,/,
there/EX
has/VBZ
been/VBN
a/DT
steep/JJ
increase/VBP
in/IN
the/DT
number/NN
of/IN
genetic/JJ
association/NN
studies/NNS
,/,
and/CC
these/DT
studies/NNS
have/VBP
successfully/RB
reported/VBN
a/DT
number/NN
of/IN
gene/NN
variants/NNS
associated/VBN
with/IN
human/JJ
complex/NN
diseases/NNS
[/(
1/CD
,/,
4/CD
,/,
5/CD
,/,
28/CD
]/)
./.
====================
Recently/RB
,/,
GWASs/NNS
,/,
a/DT
new/JJ
frontier/IN
in/IN
genetic/JJ
epidemiology/NN
,/,
have/VBP
identified/VBN
thousands/VBZ
of/IN
new/JJ
gene/NN
variants/NNS
related/JJ
to/TO
human/JJ
diseases/NNS
[/(
29/CD
]/)
./.
====================
The/DT
population-based/JJ
studies/NNS
with/IN
a/DT
large/JJ
sample/JJ
size/NN
have/VBP
increased/VBN
statistical/JJ
power/JJR
,/,
which/WDT
leads/VBZ
to/TO
smaller/JJR
variance/NN
./.
====================
However/RB
,/,
it/PRP
requires/VBZ
too/RB
much/RB
money/JJ
and/CC
takes/VBZ
too/RB
long/JJ
to/TO
collect/VB
a/DT
sufficient/JJ
number/NN
of/IN
samples/NNS
,/,
and/CC
these/DT
large-scale/JJ
studies/NNS
are/VBP
more/RBR
likely/JJ
to/TO
be/VB
affected/VBN
by/IN
systematic/JJ
bias/NNS
and/CC
noise/RB
[/(
25/CD
,/,
30/CD
]/)
./.
====================
In/IN
the/DT
current/JJ
study/NN
,/,
we/PRP
demonstrated/VBD
the/DT
effective/JJ
sample/NN
sizes/NNS
that/DT
are/VBP
required/VBN
to/TO
achieve/VB
80/CD
%/NN
statistical/JJ
power/JJR
for/IN
a/DT
case-control/JJ
study/NN
and/CC
case-parent/JJ
study/NN
separately/RB
under/IN
various/JJ
assumptions/NNS
regarding/VBG
effect/NN
size/NN
,/,
MAF/NN
,/,
disease/NN
prevalence/NN
,/,
LD/NN
,/,
case-to-control/JJ
ratio/NN
,/,
and/CC
number/NN
of/IN
SNPs/NNS
./.
====================
A/DT
lower/JJR
sample/NN
size/NN
is/VBZ
required/VBN
under/IN
the/DT
dominant/JJ
model/NN
in/IN
any/DT
assumption/NN
,/,
while/IN
the/DT
recessive/JJ
model/NN
requires/VBZ
too/RB
many/JJ
samples/NNS
under/IN
the/DT
same/JJ
assumptions/NNS
to/TO
achieve/VB
adequate/JJ
statistical/JJ
power/JJR
./.
====================
Further/RB
,/,
we/PRP
confirmed/VBD
that/IN
a/DT
lower/JJR
sample/NN
size/NN
is/VBZ
required/VBN
for/IN
testing/VBG
more/RBR
common/JJ
SNPs/NNS
with/IN
stronger/JJR
effect/NN
sizes/NNS
and/CC
increased/VBD
LD/NN
between/IN
marker/NN
allele/NN
and/CC
disease/NN
allele/NN
./.
====================
A/DT
lower/JJR
sample/NN
size/NN
is/VBZ
required/VBN
to/TO
study/VB
a/DT
common/JJ
disease/NN
than/IN
a/DT
rare/JJ
disease/NN
./.
====================
The/DT
statistical/JJ
power/JJR
increases/VBZ
by/IN
increasing/VBG
the/DT
number/NN
of/IN
controls/NNS
per/FW
case/NN
;/:
however/RB
,/,
a/DT
case-to-control/JJ
ratio/NN
exceeding/VBG
1:4/CD
does/VBZ
not/RB
yield/VB
a/DT
significant/JJ
increase/NN
in/IN
statistical/JJ
power/JJR
./.
====================
Among/IN
the/DT
parameters/NNS
tested/VBN
,/,
under/IN
the/DT
assumption/NN
of/IN
a/DT
high/JJ
level/NN
of/IN
LD/NN
between/IN
a/DT
marker/NN
and/CC
disease/NN
variant/JJ
,/,
a/DT
much/RB
reduced/VBD
sample/JJ
size/NN
is/VBZ
needed/VBN
to/TO
detect/VB
evidence/NN
for/IN
association/NN
./.
====================
Common/JJ
variants/NNS
are/VBP
more/RBR
informative/JJ
than/IN
rare/JJ
variants/NNS
in/IN
LD-based/JJ
indirect/JJ
association/NN
studies/NNS
on/IN
complex/NN
diseases/NNS
./.
====================
It/PRP
means/NNS
that/DT
researchers/NNS
can/MD
reduce/VB
the/DT
cost/JJ
by/IN
choosing/VBG
common/JJ
variants/NNS
to/TO
be/VB
genotyped/VBN
at/IN
the/DT
design/NN
stage/NN
of/IN
an/DT
LD-based/JJ
association/NN
study/NN
./.
====================
In/IN
general/JJ
,/,
the/DT
case-control/JJ
study/NN
design/NN
is/VBZ
more/RBR
powerful/JJ
than/IN
the/DT
case-parent/JJ
study/NN
design/NN
[/(
8/CD
,/,
10/CD
]/)
./.
====================
Since/IN
patients/NNS
with/IN
family/NN
histories/NNS
of/IN
the/DT
disease/NN
are/VBP
more/RBR
likely/RB
to/TO
inherit/VB
disease-predisposing/VBG
alleles/NNS
than/IN
patients/NNS
without/IN
family/NN
histories/NNS
of/IN
the/DT
disease/NN
,/,
researchers/NNS
can/MD
improve/VB
the/DT
statistical/JJ
power/JJR
by/IN
sampling/VBG
patients/NNS
with/IN
affected/VBN
relatives/VBZ
and/CC
by/IN
comparing/VBG
to/TO
controls/NNS
without/IN
any/DT
family/NN
history/NN
in/IN
case-control/JJ
association/NN
studies/NNS
[/(
13/CD
]/)
./.
====================
Genome-wide/NN
case-control/JJ
studies/NNS
have/VBP
been/VBN
used/VBN
to/TO
identify/VB
genetic/JJ
variants/NNS
that/WDT
predispose/VBP
to/TO
human/JJ
disease/NN
with/IN
model/NN
assumptions/NNS
for/IN
parameters/NNS
,/,
such/JJ
as/IN
the/DT
inheritance/NN
model/NN
./.
====================
Such/JJ
studies/NNS
are/VBP
powerful/JJ
in/IN
detecting/VBG
common/JJ
variants/NNS
with/IN
moderate/JJ
effect/NN
in/IN
the/DT
occurrence/NN
of/IN
a/DT
disease/NN
;/:
however/RB
,/,
a/DT
study/NN
with/IN
a/DT
large/JJ
number/NN
of/IN
SNP/NN
markers/NNS
by/IN
using/VBG
500/CD
K/NN
or/CC
1/CD
million/NN
chips/NNS
requires/VBZ
a/DT
large/JJ
number/NN
of/IN
samples/NNS
(/(
e.g./FW
,/,
thousands/VBZ
of/IN
cases/NNS
and/CC
controls/VBZ
)/)
to/TO
achieve/VB
adequate/JJ
statistical/JJ
power/JJR
./.
====================
A/DT
researcher/JJ
can/MD
rarely/RB
successfully/RB
conduct/NN
a/DT
large-scale/JJ
association/NN
study/NN
without/IN
collaboration/NN
using/VBG
a/DT
high-throughput/JJ
microarray/NN
chip/NN
,/,
in/IN
which/WDT
most/JJS
embedded/JJ
SNPs/NNS
reveal/VBP
a/DT
small/JJ
effect/NN
size/NN
between/IN
1.3/CD
and/CC
1.6/CD
[/(
31/CD
]/)
./.
====================
Therefore/RB
,/,
researchers/NNS
who/WP
are/VBP
planning/VBG
a/DT
genetic/JJ
association/NN
study/NN
must/MD
calculate/JJ
the/DT
effective/JJ
sample/NN
size/NN
and/CC
the/DT
statistical/JJ
power/JJR
in/IN
the/DT
design/NN
phase/NN
to/TO
perform/VB
a/DT
cost-effective/JJ
study/NN
that/IN
reduces/VBZ
false/VBP
negative/JJ
and/CC
false/VBP
positive/JJ
test/NN
results/VBZ
./.
====================
Although/IN
we/PRP
could/MD
not/RB
cover/RB
all/DT
plausible/JJ
conditions/NNS
in/IN
study/NN
design/NN
,/,
the/DT
estimates/NNS
of/IN
sample/JJ
size/NN
and/CC
statistical/JJ
power/JJR
that/DT
were/VBD
computed/VBN
under/IN
various/JJ
assumptions/NNS
in/IN
this/DT
study/NN
may/MD
be/VB
useful/JJ
to/TO
determine/VB
the/DT
sample/JJ
size/NN
in/IN
designing/VBG
a/DT
population-based/JJ
association/NN
study/NN
./.
====================
The/DT
statistical/JJ
power/JJR
for/IN
the/DT
allelic/JJ
test/NN
in/IN
a/DT
case-control/JJ
study/NN
according/VBG
to/TO
(/(
A/DT
)/)
minor/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
,/,
(/(
B/NN
)/)
disease/NN
prevalence/NN
,/,
(/(
C/NN
)/)
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
,/,
and/CC
(/(
D/NN
)/)
case-to-control/JJ
ratio/NN
(/(
M/NN
,/,
MAF/NNP
;/:
P/NN
,/,
prevalence/RB
;/:
D/NN
,/,
LD/NN
;/:
R/NN
,/,
case-control/JJ
ratio/NN
;/:
A1=1.3/RB
,/,
A2=1.5/NN
,/,
A3=2/NNP
,/,
and/CC
A4=2.5/NN
for/IN
heterozygous/JJ
odds/NNS
ratios/NNS
)/)
./.
====================
The/DT
statistical/JJ
power/JJR
according/VBG
to/TO
the/DT
number/NN
of/IN
single-nucleotide/JJ
polymorphism/NN
(/(
SNP/NN
)/)
markers/NNS
for/IN
the/DT
allelic/JJ
test/NN
in/IN
(/(
A/DT
)/)
a/DT
case-control/JJ
study/NN
and/CC
(/(
B/NN
)/)
a/DT
case-parent/JJ
study/NN
(/(
a1/NN
=/JJ
0.05/CD
,/,
a2/RB
=/JJ
1×10-7/CD
,/,
and/CC
a3/IN
=/JJ
5×10-8/CD
denote/JJ
the/DT
significance/NN
thresholds/NNS
according/VBG
to/TO
the/DT
number/NN
of/IN
markers/NNS
;/:
A1.3/RB
,/,
A1.5/NN
,/,
A2/NN
,/,
and/CC
A2.5/NN
denote/JJ
the/DT
odds/NNS
ratios/NNS
of/IN
heterozygotes/NNS
)/)
./.
====================
MAF/NN
,/,
minor/JJ
allele/NN
frequency/NN
;/:
D/NN
'/``
,/,
linkage/NN
disequilibrium/NN
./.
====================
Number/NN
of/IN
cases/NNS
required/VBD
to/TO
achieve/VB
80/CD
%/NN
power/JJR
according/VBG
to/TO
the/DT
different/JJ
genetic/JJ
models/NNS
in/IN
a/DT
case-control/JJ
study/NN
====================
Sample/JJ
sizes/NNS
with/IN
80/CD
%/NN
power/JJR
by/IN
increasing/VBG
number/NN
of/IN
SNP/NN
markers/NNS
in/IN
case-control/JJ
and/CC
case-parent/JJ
studies/NNS
====================
